Chronicles Right from Ketanserin-Masters Which Have Acheived Success

Treatment with free radical scavengers has been shown to attenuate ischemic acute renal failure in animal studies. Antioxidants or free radical scavengers are used clinically to prevent or decrease renal IRI. In the era of minimally invasive surgery (MIS), the nephron-sparing operation for small renal tumors is becoming a gold standard. While http://www.selleckchem.com/products/midostaurin-pkc412.html renal cooling is technically difficult in MIS, pre-treatment and intraoperative treatment with pharmacological agents becomes more important than ever. Carvedilol, a non-selective beta-andrenoceptor antagonist and alpha-andrenoceptor antagonist, is an antihypertensive drug with potent anti-oxidant properties and is readily used clinically.1 Carvedilol has been clinically shown to have renal protective effects. In this https://en.wikipedia.org/wiki/Ketanserin article, the authors demonstrated the long-term protective effects of carvedilol in rat models. A significant increase in the expression levels of Cu/Zn superoxide dismutase and reduction of 8-hydroxydeoxyguanosine and apoptosis levels were also demonstrated to suggest the mechanism of protective effect after treatment with carvedilol. It would be interesting to demonstrate the similar protective mechanism in human subjects who are taking carvedilol. ""Recently, the trend in all surgical disciplines has been toward less invasive treatments. High-intensity focused ultrasound (HIFU) is a non-invasive therapy for prostate cancer that has been investigated for more than 20?years. More than 30?000 patients with localized prostate cancer have been treated worldwide. As adverse events, urinary retention, bladder neck-contracture and urethral stricture have been frequently seen after HIFU. The authors reported that a small volume of resection http://www.selleckchem.com/products/liproxstatin-1.html of the prostate tissue by transurethral resection of the prostate (TURP) immediately after HIFU using the Sonablate device significantly reduced catheterization time between the HIFU-only group and the HIFU?+?TURP group (12?days vs 5?days median, P?